Search our website

Events and Presentations

Menu

Recent Presentations

World Vaccine Congress Washington 2022

  • Title: VBI-2901: Multivalent Coronavirus Vaccine
  • Date: April 21, 2022
  • Download: PDF

World Vaccine Congress Washington 2022

  • Title: Safety & Immunogenicity of a New 3-Antigen Hepatitis B Vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]
  • Date: April 20, 2022
  • Download: PDF

Recent & Upcoming Events

32nd Annual Oppenheimer Healthcare Conference

  • Date: March 16, 2022
  • Time: 10:00-10:30 AM ET
  • Webcas: Replay

B. Riley Securities 2022 Oncology Investor Conference

  • Date: January 28, 2022
  • Webcast: Replay
  • Download Presentation: PDF

World Vaccine & Immunotherapy Congress 2021

  • Title: Development of eVLP Platform for Viral Associated Cancers
  • Date: December 1, 2021
  • Download Presentation: PDF

FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

  • Date: December 1, 2021
  • Webcast: Replay

Jefferies London Healthcare Conference

  • Date: November 17, 2021
  • Webcast: Replay

Guggenheim 2nd Annual Vaccines & Infectious Disease Conference

  • Date: October 5, 2021
  • Webcas: Replay

New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

  • Date: September 29, 2021
  • Webcast: Replay
  • Download Presentation: PDF

VBI’s eVLP COVID-19 Vaccine Candidate: Initial Positive Phase 1 Data

  • Date: June 29, 2021
  • Webcast: Replay
  • Download Presentation: PDF

Canadian Liver Meeting 2021

  • Title: Higher seroproteciton rates (SPR) and higher anti-HBs concentrations in adults age 18+ achieved with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal, double-blind, randomized Phase 3 study (PROTECT)
  • Date: May 4, 2021
  • Download Oral Presentation: PDF

2021 Annual Conference on Vaccinology Research (ACVR)

  • Title: Higher seroprotection rates (SPR) and anti-HBs titers achieved in adults with a 3-antigen hepatitis B vaccine (3A-HBV) compared to a 1-antigen hepatitis B vaccine (1A-HBV): Results of the PROTECT study
  • Date: April 27, 2021
  • Download Presentation: PDF
Go top